JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2027

Conditions
Recurrent or Metastatic Nasopharyngeal CancerPatients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy
Interventions
DRUG

Mitoxantrone Hydrochloride Liposome

Mitoxantrone Hydrochloride Liposome Injection 20mg/m2, or 16mg/m2, intravenous drip, Q4W.

DRUG

JMT101 injection

JMT101 Injection 6 mg/kg, intravenous drip,

DRUG

Capecitabine

The dosage of capecitabine is 1000 mg/m2, taken orally twice daily, administered on D1-14 (Days 1-14) of each cycle, with every 3 weeks as one cycle (Q3W);

DRUG

Docetaxel injection

The dosage of docetaxel is 75 mg/m2, administered via intravenous drip on D1 of each cycle, Q3W.

DRUG

Gemcitabine hydrochloride for injection

The dosage of gemcitabine is 1000 mg/m2, administered via intravenous drip on D1 and D8 (Day 1 and Day 8) of each cycle, Q3W;

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY